Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease

Read More +

Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors

Simpson brings 22 years of industry experience to Spruce, a clinical-stage biotech developing a novel treatment for congenital adrenal hyperplasia, a rare endocrine disease

Read More +

Spruce Biosciences Provides Corporate Update on Series A Venture Financing, Leadership Team and Lead Clinical Program

Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia

Read More +


Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.